Detalles de la búsqueda
1.
Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia.
Blood;
140(17): 1875-1890, 2022 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35839448
2.
Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
Br J Haematol;
201(3): 510-519, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34970734
3.
Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
Pediatr Blood Cancer;
70(4): e30204, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36715125
4.
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Pediatr Blood Cancer;
70(6): e30295, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36975157
5.
Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol.
Pediatr Blood Cancer;
69(9): e29860, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35713168
6.
Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
Br J Haematol;
194(1): 174-178, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33843056
7.
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Br J Haematol;
193(6): 1151-1156, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33583020
8.
Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients.
Br J Haematol;
193(6): 1178-1184, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33764500
9.
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Br J Haematol;
193(3): 602-612, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33715150
10.
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.
Haematologica;
106(7): 2009-2012, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33375769
11.
Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Br J Haematol;
196(1): e6-e9, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34346071
12.
Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents.
Haematologica;
101(12): 1581-1591, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27515251
13.
Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Pediatr Blood Cancer;
63(12): 2243-2245, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27434016
14.
Laboratory characterization of the pediatric B/T subtype of mixed-phenotype acute leukemia: Report of a case series.
Am J Clin Pathol;
2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38513276
15.
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
J Immunother Cancer;
12(6)2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38844406
16.
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Cancer Med;
13(8): e7172, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38651186
17.
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
J Cancer Res Clin Oncol;
149(8): 4629-4637, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36169717
18.
Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy.
Cancers (Basel);
14(21)2022 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36358863
19.
Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.
Leuk Res;
100: 106491, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33340851
20.
Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αß T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia.
Bone Marrow Transplant;
56(7): 1614-1624, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33594278